stockportfolio.pro
Stocks / DXCM vs RVMD
DXCM vs RVMD: Which Stock Is the Better Buy?
DexCom, Inc. and Revolution Medicines, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
RVMD is the larger company ($31.3B vs $27.5B). On the fundamentals, DXCM has the stronger return on equity (30.5% vs -69.3%). Neither shows an obvious red flag in the filings. Full numbers below — the stronger figure on each row is in green.
AI verdict — DXCM vs RVMD, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| DexCom, Inc. (DXCM) | Revolution Medicines, Inc. (RVMD) | |
|---|---|---|
| Market cap | $27.5B | $31.3B |
| Revenue (latest FY) | $4.66B | $0 |
| Net income (latest FY) | $836.30M | $-1.13B |
| Revenue growth (5y CAGR) | 19.3% | — |
| Net margin | 17.9% | — |
| Return on equity | 30.5% | -69.3% |
| P/E ratio | 30.6 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 0 |
| Positive free cash flow | Yes | No |
Compare with another company:
See the full DXCM vs RVMD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open DXCM's full financials → Open RVMD's full financials →More comparisons
Frequently asked questions
Which is bigger, DXCM or RVMD?
Revolution Medicines, Inc. is larger by market capitalization — $31.3B versus $27.5B.
Which grows faster, DXCM or RVMD?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.